Skip to content

    BIOMARIN PHARMACEUTICAL (BMRN) stock price & financials

    View BMRN earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+10.2% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $745.74M
    $747.31M
    $745.14M
    $825.41M
    $776.13M
    +4.1%
    $874.57M
    +17.0%
    $766.21M
    +2.8%
    $989.71M
    +19.9%
    Strengthening
    Operating Profit
    $113.89M
    $161.41M
    $223.89M
    $276.89M
    -$46.69M
    -141.0%
    -$44.61M
    -127.6%
    $129.64M
    -42.1%
    $110.92M
    -59.9%
    Weakening
    Net Profit
    $106.08M
    $124.94M
    $185.69M
    $240.53M
    -$30.74M
    -129.0%
    -$46.57M
    -137.3%
    $105.53M
    -43.2%
    $44.76M
    -81.4%
    Weakening
    EPS
    $0.56
    $0.97
    $1.25
    $-0.16
    -128.6%
    $0.55
    -43.3%
    $0.23
    -81.6%
    Weakening
    Other Income
    Interest
    $2.97M
    $2.58M
    $2.86M
    $2.68M
    $2.58M
    -13.1%
    $2.78M
    +7.8%
    $14.96M
    +422.5%
    $63.30M
    +2262.6%
    Strengthening
    Depreciation
    Profit before Tax
    $134.44M
    $169.64M
    $238.09M
    $297.87M
    -$26.32M
    -119.6%
    -$27.15M
    -116.0%
    $141.20M
    -40.7%
    $61.38M
    -79.4%
    Weakening
    MarginsOPM
    15.3%
    21.6%
    30.1%
    33.5%
    -6.0%
    -139.4%
    -5.1%
    -123.6%
    16.9%
    -43.7%
    11.2%
    -66.6%
    Weakening
    Tax
    21.1%
    26.4%
    22.0%
    19.3%
    -16.8%
    -179.6%
    -71.5%
    -371.4%
    25.3%
    +14.8%
    27.1%
    +40.7%
    Weakening
    ReturnsROIC
    34.8%
    41.0%
    60.9%
    78.9%
    -10.1%
    -129.0%
    -15.3%
    -137.3%
    34.6%
    -43.2%
    14.7%
    -81.4%
    Weakening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$493.98M$437.45M$649.16M$587.28M$724.53M$755.13M$942.84M$1.31B$874.00M
    Short-Term Investments
    Total Current Assets$2.06B$1.94B$2.34B$2.27B$2.75B$2.96B$3.23B$3.95B$3.97B
    Net PP&E$948.68M$1.06B$1.08B$1.07B$1.11B$1.11B$1.07B$987.75M$989.99M
    Goodwill$197.04M$197.04M$196.20M$196.20M$196.20M$196.20M$196.20M$196.20M$655.75M
    Intangibles$491.81M$456.58M$417.27M$388.65M$338.57M$294.70M$255.28M$213.84M$4.88B
    Total Assets$4.43B$4.69B$5.85B$6.00B$6.38B$6.84B$6.99B$7.59B$11.72B
    LiabilitiesTotal Current Liabilities$523.24M$932.50M$492.55M$546.50M$588.88M$1.18B$606.99M$759.03M$1.66B
    Short-Term Debt$0$658.20M
    Long-Term Debt$597.18M$3.53B
    Long-Term Leases$44.09M$40.48M$31.88M$26.33M$38.05M$30.50M$36.58M
    Total Liabilities$1.46B$1.57B$1.74B$1.74B$1.77B$1.89B$1.33B$1.51B$5.40B
    EquityCommon Stock & APIC$178.0K$180.0K$182.0K$184.0K$186.0K$189.0K$191.0K$192.0K$194.0K
    Retained Earnings-$1.69B-$1.72B-$861.61M-$930.76M-$789.20M-$621.55M-$194.69M$154.21M$304.50M
    Total Equity$2.97B$3.12B$4.10B$4.27B$4.60B$4.95B$5.66B$6.09B$6.32B
    HighlightsNet Cash / (Debt)$714.50M-$3.31B

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$20.21M$48.26M$85.36M$304.54M$175.90M$159.26M$572.84M$827.99M$857.09M
    Cash from Investing$264.35M-$31.03M-$53.62M-$366.31M-$20.03M-$111.24M$136.49M-$414.24M-$4.75B
    Cash from Financing-$388.01M-$74.67M$181.12M-$48.0K-$18.65M-$18.73M-$526.45M-$42.39M$3.55B
    SummaryCapital Expenditure-$144.62M-$145.03M-$114.31M-$95.58M-$120.96M-$96.69M-$85.42M-$103.04M-$118.91M
    Free Cash Flow-$124.41M-$96.76M-$28.95M$208.96M$54.94M$62.57M$487.42M$724.96M$738.18M
    FCF Margin-8.3%-5.7%-1.6%11.3%2.6%2.6%17.1%22.5%21.7%

    Ratios